SHL Group is looking forward to exhibiting at the 2019 Pharmapack, Europe’s dedicated pharmaceutical packaging and drug delivery event from 6-7 February in Paris, France.
At the centre of this year鈥檚 exhibition is Molly庐 2.25, SHL鈥檚 high-volume variation of its classic Molly庐 auto-injector, which is designed with a preconfigured technology to help pharmaceutical companies minimise initial equipment investments and speed up development timelines.
Boasting an intuitive design that meets a variety of patient handling profiles, Molly庐 2.25 supports the trend for injection volumes in the 1-2.25ml range to meet the increasing need for the simple delivery of larger doses. SHL is also looking forward to the market introduction of the first drug product based on the Molly庐 2.25 programme.
Another highlight at this year鈥檚 event is the range of auto-injectors built with SHL鈥檚 Needle Isolation Technology (NIT庐). This proprietary technology allows cartridge-based injection devices to be built as easy-to-use auto-injectors with permanently hidden needles.
SHL鈥檚 global director of marketing Magnus Fastmarken said: 鈥淭he NIT庐 is a true problem solver because cartridges not only open up a world of opportunities for pharma companies, it also offers patients a safe and intuitive experience without sacrificing usability.鈥�
This year, SHL is again pairing up with Innovation Zed to present InsulCheck at Pharmapack鈥檚 Innovation Gallery. This year鈥檚 display, InsulCheck Connect, is a smart pen injector add-on that displays the time elapsed since the last injection. It can be connected to 3rd party service applications to track insulin injection. InsulCheck Connect is compatible with a variety of existing insulin injection pens on the market and can be customised to support other pen injector projects.
Visitors are invited to explore SHL鈥檚 innovative injectable drug delivery solutions at Stand B44 at the Paris Expo Porte de Versailles.